Certara Appoints John Reynders as New Independent Board Member

Core Insights - Certara, Inc. has appointed John Reynders, PhD, to its Board of Directors effective October 15, 2024, enhancing its leadership with expertise in artificial intelligence and data science [1][2] Company Overview - Certara is a leader in model-informed drug development, utilizing biosimulation software and services to transform traditional drug discovery and development [3] - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries [3] Leadership Expertise - Dr. Reynders brings over 25 years of experience in the pharmaceutical and tech industries, having held significant roles at Moderna, Neumora, Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly, and Celera [2] - His previous role as the founding CIO of Moderna involved leading data-sciences capabilities for mRNA therapies, showcasing his strong background in the intersection of data and life sciences [2][3] Future Directions - Dr. Reynders expressed enthusiasm about contributing to Certara's growth and leveraging its unique biosimulation portfolio and scientific expertise [3]